Internal Medicine · Omaha, NE
NPI
1689961484
Since 2011
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
8303 Dodge St Ste 250
Omaha, NE, 68114
Phone (402) 334-4773
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
135,209 services
Medicare patients, 2024
405
Average age 75
Drug cost, 2024
$2.3M
1,056 prescriptions
Company payments, 2025
$2,515
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Timothy H Dorius was code J9271 (injection, pembrolizumab, 1 mg), 13,801 times for 12 patients. In total Timothy H Dorius billed 135,209 services in 128 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 13,801 | 12 | $44.53 | $615K |
| J0897 Injection, denosumab, 1 mg | Office | 5,460 | 17 | $20.41 | $111K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 4,200 | 12 | $0.11 | $445 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 3,740 | 12 | $6.51 | $24K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,188 | 32 | $0.09 | $108 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 730 | 18 | $0.76 | $552 |
| 99214 Office E&M - Established | Office | 704 | 282 | $80.31 | $57K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 608 | 13 | $0.07 | $45.48 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 444 | 63 | $0.49 | $219 |
| 96372 Injection Administration | Office | 273 | 58 | $9.19 | $2,508 |
| 96413 Chemotherapy Administration | Office | 264 | 49 | $82.76 | $22K |
| 96375 Injection Administration | Office | 224 | 30 | $10.22 | $2,289 |
| 96367 Intravenous Infusion, Hydration | Office | 177 | 33 | $18.65 | $3,301 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 114 | 102 | $12.42 | $1,416 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 106 | 12 | $4.41 | $468 |
By year: 2022 $2.2M for 183,797 services; 2023 $2.9M for 192,518 services; 2024 $2.2M for 135,209 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 55 | 39 | $7.33 | $403 |
| 80053 Clinical Chemistry | 42 | 31 | $10.10 | $424 |
Medicare prescription drug claims, 2024
In 2024, the drug Timothy H Dorius prescribed most often to Medicare patients was Anastrozole, with 77 prescriptions and refills. In total Timothy H Dorius wrote 1,056 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 77 | 203 | 27 | $1,398 |
| Prednisone Generic | 69 | 96 | 21 | $380 |
| Letrozole Generic | 59 | 157 | 26 | $1,221 |
| Lenalidomide Generic | 49 | 49 | Under 11 | $660K |
| Hydroxyurea Generic | 44 | 79 | 16 | $1,019 |
| Ondansetron Hcl Generic | 40 | 41 | 33 | $455 |
| Eliquis Apixaban | 35 | 45 | Under 11 | $27K |
| Tamoxifen Citrate Generic | 34 | 90 | 15 | $950 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 28 | 28 | 18 | $335 |
| Tramadol Hcl Generic | 28 | 28 | 12 | $112 |
| Prochlorperazine Maleate Generic | 28 | 28 | 24 | $349 |
| Acyclovir Generic | 25 | 49 | Under 11 | $328 |
| Dexamethasone Generic | 24 | 34 | 18 | $688 |
| Xarelto Rivaroxaban | 22 | 38 | Under 11 | $21K |
| Gabapentin Generic | 19 | 19 | Under 11 | $160 |
Brand drugs: 177 claims; generic drugs: 879 claims; opioid claims: 78.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Timothy H Dorius $2,515 ($2,515 in general payments such as food, travel and fees) from 22 companies. The largest payer was PharmaEssentia USA Corporation with $2,048.
| Company | Payments | Amount |
|---|---|---|
| PharmaEssentia USA Corporation 6446.TW | 1 | $2,048 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $68.49 |
| Intera Oncology, Inc | 2 | $43.84 |
| Pharmacosmos Therapeutics Inc. | 2 | $42.85 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $33.75 |
| Gilead Sciences, Inc. GILD | 2 | $32.68 |
| Daiichi Sankyo Inc. 4568.T | 1 | $23.87 |
| Coherus Oncology, Inc. CHRS | 1 | $23.78 |
| Astellas Pharma US Inc 4503.T | 1 | $23.24 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $22.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.